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Much confusion exists concerning the relationship between the proteolytic activity 
of plasma and the coagulation of blood. Evidence has been offered both to support 
and deny the hypothesis that the activated proteolytic enzyme of plasma accelerates 
blood clotting. The dab relating the proteolytic activity of plasma to clotting were 
reviewed by Nolf (1), by Ferguson (2),  and by Macfarlane and Biggs (3). Delezenne 
and Pozerski (4) in 1903 reported that serum became proteolytic following the addition 
of chloroform. Nolf (5) observed that chloroform-treated serum was capable of clotting 
solutions of fibrinogen, and he suggested that proteolysis was a necessary step in the 
clotting process  (1).  The  chloroform-activated proteolytic property  of plasma  was 
shown by Tagnon (6) to be present in its acid-insoluble globulin fraction. This fraction, 
too, was reported to clot fibrinogen solutions as well as oxalated plasma (7). 
The proteolytic properties of plasma globulin can be activated not only by chloro- 
form,  but  also by bacteria-free  filtrates  of cultures  of beta  hemolytic streptococci 
(8-11).  The active principle present  in  these filtrates  has been called streptococcal 
fibrinolysin  (12)  or  streptokinase  (13).  Ferguson  (14)  observed  that  a  fraction  of 
plasma  globulin,  activated  by  streptococcal  fibrinolysin,  was  thromboplastic,  and 
concluded  that  the  proteolytic  enzyme of plasma  plays  a  r61e in  blood  clotting. 
Further  evidence suggesting a  relationship  between  proteolysis  and  coagulation 
has been provided by a study of trypsin inhibitors. The inhibitors of trypsin derived 
from pancreas and soy bean were observed to inhibit the activity of the proteolytic 
enzyme of plasma (15, 16). These substances also inhibited blood coagulation (17-19), 
lending support to the belief  that the proteolytic enzyme of plasma participates  in 
the  clotting  mechanism. 
On the other hand, certain data cast doubt that proteolysis plays any physiologic 
r61e in dotting. In particular,  it was reported that purified preparations of the pro- 
teolytic enzyme of plasma did not convert prothrombin to thrombin, nor clot fibrin- 
ogen (20, 21).  Furthermore,  preparations of plasma globulin were said to be separable 
into two fractions. One of these fractions promoted clotting, while the other exhibited 
proteolytic activity (22). 
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In  the  experiments  to  be  reported,  an  attempt  was  made  to  determine 
whether any relationship exists between the plasma proteolytic activity and the 
clotting of the blood. A  globulin fraction of plasma, rich in proteolytic activity, 
was prepared. This fraction was apparently not thrombic, since it did not clot 
decalcified plasma, and it had little or no thromboplastic activity. It failed to 
clot platelet-deficient hemophilic plasma,  or clotted it only after  great  delay. 
This globulin fraction accelerated the clotting of the platelet-deficient plasma 
of normal individuals, but no relationship was demonstrable between its clot- 
accelerating and  its  proteolytic  activities. The  evidence  to  be  presented  in- 
dicates that no obvious relationship exists between the proteolytic activity of 
plasma and the physiologic clotting of blood. 
Methods and Materials 
Nomemlature.--The  nomenclature to  be  used  was  discussed  in an  earlier  publication 
(23). The enzyme present in the acid-insoluble globulin of plasma will be called the plasma 
proteolytic enzyme, a term synonymous with plasmin (13) or fibrinolysin (21). This enzyme 
is ordinarily present in plasma as an inactive precursor. The filterable principle of cultures 
of hemolytic streptococci  which activates the precursor will be called streptococcal  fibrinolysin 
(12) although the newer term streptokinase (13) is frequently used in the current literature. 
As in previous studies, the term enzyme will be used to designate the crude enzyme preparation 
used, and does not imply a purified product or even a  single substance. The name thrombo- 
plastin will be applied to describe  a  substance or substances which initiate the conversion 
of prothrombin to thrombin in the presence of calcium. 
Preparation of Emyme.--The general methods employed in the preparation of precursor 
were  detailed elsewhere  (23,  24).  Briefly,  a  globulin fraction was separated from oxalated 
plasma in the following manner. Oxalated plasma was diluted with 19 volumes of distilled 
water and the solution was acidified  to pH 5.2,  as measured with a  Beckman laboratory 
model G pH meter. The resultant precipitate was separated by centrifugation and dissolved 
in a buffer solution. In the experiments to be described,  the buffer solution consisted of 7.30 
gm. of sodium chloride,  2.76 gm. of barbital, and 2.05 gm. of sodium barbital, diluted to a 
volume of  1 liter with distilled water. The buffer,  then, was  composed  of 0.125  M sodium 
chloride,  buffered  by 0.025  M barbital, at pH  7.5. 
Preparation of Streptococcal Filtrate.--In most experiments, the sterile filtrate of a 24 hour 
culture of the H46A strain of group C hemolytic streptococcus  in trypticase soy broth was 
used  as a  crude fibrinolysin (23).  In some  experiments, purified streptococcal fibrinolysin 
(streptokinase), dissolved in barbital buffer, was used  1. This preparation, containing 36 units 
per microgram (25), was dissolved in buffer in a concentration of 10,000 units per ml. of solu- 
tion, and was stored in a refrigerator at -10°C. until use. 
Measurement of Proteolysis.--Enzymatic  activity was determined by methods previously 
described  (23, 24). The enzyme-substrate mixture was incubated at 37~C. and the degree of 
proteolysis was  determined by  assaying  the  precipitable protein  turbidimetrically before 
and after digestion.  The substrate used was a 0.3 per cent solution of casein (vitamin-test, 
Lot No.  17218, General Biochemicals,  Inc.). Three gin. of casein was dissolved  at 56°C. in 
900 ml. of water containing 6 ml. of 1 N sodium hydroxide.  To this was added 3 ml. of 1 N 
hydrochloric acid,  and the volume brought to  1 liter with water.  Thus the final solution 
contained 3 mg. of casein per ml., in 0.003 N sodium hydroxide and 0.003 N sodium chloride. 
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To measure the precipitable protein, 2 ml. of 12.5 per cent hydrochloric acid and 0.5 ml, of 
20 per cent sulfosalicylic acid were added in rapid succession to a  1 ml. aliquot of the solution 
to be tested. Maximal turbidity appeared in about 5 minutes, and was read in  a  cuvette  of 
8 mm. internal diameter with a  Coleman, Jr. spectrophotometer, at a wave length of 420 m/z. 
With the tube, instrument, and lot of casein used, an optical density of 0.265  was equivalent 
to a  concentration of 1.0 mg. of casein per ml. of enzyme-substrate mixture. 
The proteolytic enzyme of plasma digested the preparation of casein used in direct pro- 
portion to the concentration of the enzyme preparation until approximately 0.8 mg. of casein 
per ml. remained. Beyond this point, digestion was not linear. For this reason it was conven- 
ient to express the activity of proteolytic enzyme preparations in  terms of arbitrary  diges- 
tion units, such that 50 digestion units of enzyme digested 0.50 mg. of casein per ml. of enzyme- 
substrate mixture in 1 hour. It should be emphasized that the casein used as substrate dif- 
fered from that used in experiments reported earlier. 
Preparation of Prolhrombin-Deflcient Plasma.---Oxalated  (23)  human plasma was shaken 
with approximately one-fifth its volume of powdered barium sulfate, and incubated at 37°C. 
for  10  minutes.  The  barium sulfate was  then removed by  two  successive centrifugations. 
The supernatant plasma was tested for the presence of prothrombin by the addition of suitable 
amounts of calcium and thromboplastin derived from rabbit brain (26). In the barium-sulfate- 
treated  plasmas  used  for  the  preparation of proteolytic enzyme,  no prothrombin was  de- 
tectable  by  this method. 
Preparation of Platdet-Deficient Plasma.--Blood  was collected from the antecubital veins 
of fasting human subjects, using needles and syringes coated with silicone (27).  The blood 
was transferred immediately to lusteroid centrifuge tubes lined with silicone.  Then, without 
the addition of anticoagulants, it was centrifuged for 10 minutes at 20C. in an angle centrifuge 
(tim diameter 10 inches) at 12,500 lz.p.x*. The upper two thirds of the plasma was transferred 
with a  silicone-lined pipette to a  silicone-treated test tube, and stored in an ice bath until 
used.  Platelet counts were  performed  on this plasma,  using methods previously described 
(27). 
Measurement of Clotting Time.--Clotting times were  determined in uniform, acid-washed, 
pyrex Wassermann tubes of 11 mm. internal diameter. In most experiments, the tubes were 
lined with silicone. The tubes were submerged in an ice bath. Suitable amounts of the solution 
to  be tested and of platelet-deficient plasma were added in succession to each tube.  After 
thorough mixing, the tubes were transferred to a water bath at 37°C.,  and the clotting times 
determined  to  the  nearest half minute.  Each  clotting  time  was  determined  in  duplicate. 
Measurement of Lysis  Time.--The  tubes  containing clotting mixtures were  closed  with 
rubber stoppers and incubated at 37°C.  in a  water bath. After clotting occurred, the tubes 
were inspected at frequent intervals for evidences of fibrinolysis. The clot lysis time was the 
interval which elapsed  from  the  time of  mixing of  platelet-deficient plasma  and  the  test 
solution until the clot was completely dissolved (28). It was not practical to maintain sterility 
during these experiments, but there was no evidence that bacterial contamination influenced 
the results of  clot lysis tests. 
Measurement of Thromboplastic Activity.--The  thromboplastic activity of preparations of 
globulin was  measured  by  determining their clot-promoting effects on  hemophilic plasma. 
Platelet-deficient hemophilic plasma failed to  clot in silicone-treated tubes when incubated 
for  indefinite  periods  at  37°C.  (27).  However,  tissue  thromboplastin  clotted  hemophilic 
plasma and platelet-deficient normal plasma equally rapidly. For this reason, platelet-deficient 
hemophilic plasma was used to detect the presence of thromboplastin in the globulin prepara- 
tions. Three-tenths ml. of platelet-deficient hemophilic plasma was added  to 0.6 mi. of the 
solution to be tested, and the mixture was then incubated at 37°C.  in a  water bath. Even 
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hemophilic plasma within a few minutes. Therefore, failure of hemophilic plasma to clot within 
a few minutes after the addition  of a globulin preparation was believed to be evidence that 
this preparation was deficient in thromboplastic activity. 
EXI~ER  I~G~.NTAL 
1.  The  Relationship  between  the  Proteolytic  Activity  of  a  Plasma  Globulin 
Fraction,  and Its Clot-Accelerating _Properties.--In  preliminary  experiments,  a 
study was made of the clot-accelerating properties of proteolytic enzyme pre- 
pared  from fresh  oxalated  normal human  plasma and activated  with  chloro- 
form  (23,  24).  Such  chloroform-activated  enzyme  clotted  decalcified  plasma. 
This thrombic property was not present in preparations of proteolyti c enzyme 
made from plasma from which the prothrombin had first been removed. There- 
fore,  in  subsequent  experiments  the  proteolytic  enzyme  was  prepared  from 
prothrombin-deficient  plasma. 
The globulin  fraction of normal human plasma has been said  to contain  an 
accelerator globulin  (29-32)  and a  plasma thromboplastin  (33), both of which 
have been reported to accelerate the conversion of prothrombin  to thrombin. 
In preliminary  experiments,  it became evident  that plasma  globulin  contain- 
ing these  substances accelerated  the  clotting of normal plasma independently 
of the proteolytic activity of the preparation.  Various expedients were used to 
minimize the effects of these known clot accelerators, so that any clot-promot- 
ing activity of plasma proteolytic enzyme might be detected. Platelet-deficient 
hemophilic  plasma  has  been  said  to  be  deficient  in  plasma  thromboplastic 
activity (33). For this reason, in some experiments platelet-deficient hemophilic 
plasma was used as a  source of enzyme. Prolonged storage of plasma, or heat- 
ing plasma to 56°C.  for 30 minutes,  has been said to diminish the activity of 
both accelerator globulin and plasma thromboplastin  (34, 35). In different ex- 
periments with hemophilic plasma, both storage and heating were used for this 
purpose. When normal plasma was used as a source of enzyme, it was necessary 
to heat the plasma to 58°C. for 30 minutes in order to decrease materially the 
thromboplastic  activity  of  its  globulin  fraction.  Fibrinogen  was precipitated 
when the plasma was incubated at 56 or 58°C. 
In a  typical experiment,  platelet-deficient  plasma, low in  thrombeplastie activity, was 
obtained from a patient with hemophilia.  This plasma was oxalated  and stored at 4°C. for 
67  days, in  order to decrease  the activity of its thromboplastin and  accelerator  globulin. 
The plasma was then shaken  with one-fifth its volume of powdered barium sulfate  and in- 
cubated at 37°C. for 10 minutes,  to remove prothrombin.  The barium sulfate was separated 
by centrifugation.  The  SUlSernatant, prothrombin-deficient  plasma was heated  in  a  water 
bath at 56°C. for 30 minutes, to reduce further the activity of its thromboplastin  and accelera- 
tor globulin, and to precipitate fibrinogen. The heated plasma was centrifuged,  and a 6 ml. 
portion of the supernatant fluid was diluted  with 19 volumes of distilled water in a 200 ml. 
round bottomed centrifuge  tube. Sufficient 1 per cent acetic acid was added to bring the pH 
to 5.2, and the precipitate which appeared was separated  by centrifugation.  The supematant 
fluid was discarded.  The precipitate, an acid-insoluble globulin fraction  of the plasma, was 
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Two ml. of the solution of globulin was pipetted  into each of two 50 ml. round bottomed 
centrifuge tubes. To the first was added I ml. of a solution of purified streptococcal fibrinolysin 
(streptokinase) containing 10,000 units per ml. To the second tube was added 1 ml. of buffer, 
as a control. The tubes were stoppered and allowed to stand for 5 minutes at room temperature 
(32°C.). The contents of each of the tubes was then diluted  to 40 ml. with distilled water, 
acidified to pH 5.2 with one-tenth per cent acetic acid, and the resultant  precipitate was re- 
dissolved in 3 mL of buffer. The first of these precipitates,  then,  was a solution of globulin 
containing fibrinolysin-activated enzyme in the same volume of fluid as the original sample 
of plasma. The second preparation  was a solution of globulin containing an equal concentra- 
tion of unactivated  precursor of plasma proteolytic enzyme. 
The clot-accelerating properties  of the two globulin preparations  were compared.  Each 
globulin was diluted  serially in fourfold and twofold steps with buffer, and 0.4 ml. of each 
dilution was pipetted into a silicone-treated clotting tube. Two-tenths ml. of normal platelet- 
deficient plasma was then added to each tube, and the clotting time at 37°C. recorded. Each 
tube was closed with a rubber stopper, and the clots were observed for evidence of fibrinolysis. 
Simultaneously, the proteolytic activity of the two globulin preparations  was assayed by 
their ability  to hydrolyze casein. 
In the experiment  just  described,  the  preparation  of fibrinolysin-activated 
plasma proteolytic enzyme contained 440 digestion units per ml. In contrast, 
the control preparation  of globulin,  containing the unactivated precursor, did 
not possess any caseinolytic activity measurable by the technique used. 
The clotting times  of mixtures  of platelet-deficient  plasma and each of the 
globulin preparations are recorded in Table I. In the tubes containing control, 
unactivated globulin, clot formation was accelerated in proportion to the con- 
centration  of  globulin.  In  those  tubes with  the  highest  concentrations  of fi- 
brinolysin-activated enzyme, no clotting occurred at all. Presumably, proteolysis 
was sufficiently rapid so that  the prothrombin  or fibrinogen was digested  be- 
fore clotting could occur. In tubes with lesser amounts of active enzyme, the 
clotting times were the same as in those containing corresponding  amounts of 
the  control,  unactivated  globulin.  It was evident  that proteolysis  took place 
in all  the  tubes  with activated plasma  proteolytic enzyme, since the  clots in 
all these tubes  lysed more rapidly than  the control clots. 
Plasma  proteolytic enzyme,  then,  was prepared  by techniques  designed  to 
minimize the activity of such interfering substances as prothrombin, thrombin, 
fibrinogen,  plasma  thromboplastin,  and accelerator globulin.  This proteolytic 
preparation  of  globulin  accelerated  the  clotting  of  normal  platelet-deficient 
plasma.  However,  its  clot-accelerating  effect  was  identical  with  that  of  the 
same fraction of globulin in which the enzyme had not been activated. 
2.  The Influence  of Plasma Proteolytic Enzyme on the Clotting of Hemophilic 
Platelet-Deficient Plasma.--Hemophilic  platelet-deficient  plasma  was observed 
to be  spontaneously incoagulable  when incubated  at  37°C.  (27).  Presumably 
this  was  because  hemophilic  plasma  is  deficient  in  plasma  thromboplastic 
activity  (33).  If plasma proteolytic enzyme had thromboplastic  properties,  it 
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The  thromboplastic  activity  of  the  preparations  of globulin used in  the  experiments 
described in section  1 was tested  in the following manner. Three-tenths  ml. of hemophilic 
platelet-deficient plasma was added  to 0.6 ml. of each solution of globulin. The tubes were 
closed with rubber  stoppers, incubated  at 37°C. in a water  bath, and the clotting times re- 
corded. In many tubes, no clots formed. Conceivably, this may have been due to the digestion 
of prothrombin or fibrinogen by plasma  proteolytic  enzyme. For this  reason  the following 
test was performed  for the presence of prothrombin  and fibrinogen. Ninety minutes  after 
the platelet-deficient plasma and the globulin solutions were mixed, an aliquot of 0.2 ml. was 
transferred to a soft glass test tube containing 0.1 ml. of thromboplastin  derived from rabbit 
brain.  Coagulation of this mixture indicated the presence of prothrombin and fibrinogen. 
TABLE  I 
Effect  of Proteolyt~c Enzyme of Plasma  on the Rate  of Clotting of Normal  Platelet-Deficient 
Plasma 
Concentration  of globufin 
Original plasma concentration 
original plasma concentration 
Buffer control 
Streptococcal fibrlnolysin-  [ 
activated globulin (440 diges- [ 
tion units/ral.) 
•  •  Clot lysis  Clottin~ time  t'  ] 
in dupncate  in dulpn]iecate [ 
tnln. 
oooo 







Control  globulin 
(0 digestion tmits/ml.) 
Clotting time 
in duplicate 
hrs.  min. 
--  4.0,  4.5 
6.0, 5.5 
0.2, 0.2  6.0, 6.0 
2.5, 2.5  8.0, 7.0 
20, 20  8.0, 8.5 
44, 44  10.0, 10.0 
44, 44  10.5, 10.0 
52, 52  15.0, 14.0 








72  72 
72, 72 
52, 52 
0.2 ml. portions  of normal platelet-deficient  plasma  (17 platelets/mm, s) were added  to 
0.4 ml. of each globulin solution. The clotting  times of the mixtures were determined  in 
silicone-treated tubes at 37°C. 
* Incomplete clots. 
The  thromboplastic  activity  of the preparations  of globulin  is  recorded in 
Table  II.  In  high  concentration,  the  preparations  of  plasma  globulin  were 
weakly  thromboplastic.  The  same  preparations,  diluted  16  times,  failed  to 
promote  the  clotting  of  hemophilic  plasma,  although  an  identical  amount 
appreciably accelerated the clotting of normal platelet-deficient plasma (Table 
I).  In repeated  experiments,  no differences were noted between  the  clot-pro- 
moting effects of preparations containing fibrinolysin-activated enzyme and the 
same globulin fractions containing the inactive precursor of plasma proteolytic 
enzyme. Furthermore,  the failure of plasma proteolytic enzyme to clot hemo- 
philic plasma was not due to the digestion of prothrombin or fibrinogen.  The 
subsequent  addition  of  thromboplastin  derived  from rabbit  brain  promptly 
clotted  plasma  which  had  been  mixed  with  the  preparations  of  globulin 
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3.  The Effect  of Purified  Streptococcal  Fibrinolysin  on  the  Clotting  Time  of 
Normal  and Itemophilic  Platelet-Deficient  Plasma.--The  globulin preparations 
used  in  the  experiments  described  in  the  preceding  sections  accelerated  the 
clotting of normal platelet-deficient  plasma.  It is possible  that  this  property 
of the globulin fraction may have masked a  clot-accelerating action of plasma 
proteolytic  enzyme.  A  method  of activating  the  proteolytic  enzyme  in  the 
platelet-deficient plasma, without  the addition of globulin, would help to clarify 
the role of proteolysis in blood coagulation.  It has long been known that  the 
proteolytic  activity  of plasma  can  be  activated  directly  by  the  addition  of 
TABLE II 
Effect of Proteolytic Enzyme of Plasma on the Rate of Clotting of Hemophilic Platelel-Deficient 
Plasma 
Concentration  of globulin 
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0.2  ml.  portions  of hemophilic platelet-deficient  plasma  (80 platelets  per  c.mm.) were 
added  to 0.4 ml.  of each globulin solution. The clotting  times of the mixtures  were de- 
termined in silicone-treated tubes at 37°C. After 90 rain. 0.2 ml. portions of the unclotted 
mixtures were added  to 0.1 ml. of rabbit brain  thromboplastin  and  the  clotting  times re- 
corded. 
* Incomplet~ clots. 
potent preparations of streptococcal fibrinolysin (8). Therefore, the effect of a 
purified  preparation  of  streptococcal  fibrinolysin  upon  the  clotting  time  of 
normal and hemophilic platelet-deficient  plasma  was studied. 
A solution of 10,000 units per ml. of purified streptococcal flbrinolysin in buffer was serially 
diluted with buffer. Six-tenths ml. of each dilution of streptococcal fibrinolysin was pipetted 
into silicone-treated test tubes. Three-tenths  ml. of platelet-deficient plasma was then added 
to each tube. The tubes were closed with rubber  stoppers,  the mixtures  incubated  at 37°C 
in a water bath, and the clotting and lysis times recorded. 
The solutions of streptococcal fibrinolysin failed to shorten the clotting time 
of normal platelet-deficient  plasma  (Table  III). The amount of streptococcal 
fihrinolysin added was apparently adequate to activate the proteolytic enzyme 
present  in  the plasma.  As evidence of this,  fibrinolysis occurred most rapidly 
in  those  tubes  with  the  highest  concentrations  of streptococcal  fibrinolysin. TABLE  III 
The Effect of Purified  Streptococcal  Fibrinolysin  on the Rate  of Clotting  of Normal  Platdet- 
Deficient Plasma 
Final concentration  of strepto-  coccal fibrinolysin  Clotting time in duplicate  Lysis time in duplicate 
units/ml. 













12.5,  19 
16.5,  16 
16.5,  15 
16.5,  19 
16.5,  16.5 











0.6  ml.  portions of  solutions of purifed  streptococcal fibrinolysin in buffer were added 
to 0.3  ml. of platelet-deficient plasma  (17  platelets/mm?)  and the clotting times at 37°C. 
determined. 
* Incomplete clots. 
:~ This  experiment  suggested  that  purifed  streptococcal  fibrinolysia was  less  effective 
in high than in lower concentrations. This phenomenon was described by Christensen and 
MacLeod  (13).  Experiments  on  the  caseinolytic  activity  of  globulin activated  with  the 
purified streptococcal fibrinolysin used in this study confirmed this. 
TABLE IV 
Effect  of Purified  Streptococcal  Fibrinolysin  on  the  Rate  of Clotting  of ltemophilic Platelet- 
Deficient  Plasma 
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oo  oo 
oo  oo 
oQ  oo 
ca. 1500, ca. 1500 





17,  17 
17,  17 
18,  18 
17, 17 
0.3  ml.  portions of  hemophilic platelet-deficient plasma  (45  platelets per  c.mm.) were 
added  to 0.6 ml. of solution of streptococcal fibrinolysin in buffer. The  mixtures were ob- 
served for clotting for 24 hours at 37°C.  After 24 hours 0.2  ml. portions of  the unclotted 
mixtures were added  to 0.1  ml.  of rabbit brain thromboplastin and the clotting times re- 
corded. 
* The clots formed  on the addition of  thromboplastin were  incomplete in  the mixtures 
containing the highest concentrations of streptococcal fibrinolysin. 
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Platelet-deficient hemophilic plasma,  incubated  in  silicone-treated tubes, 
failed to clot upon the addition of streptococcal fibrinolysin  (Table IV). This 
suggests that neither activated plasma proteolytic enzyme, nor the preparation 
of streptococcal fibrinolysin itself was thromboplastic. Twenty-four hours after 
the platelet-deficient hemophilic plasma  and streptococcal fibrinolysin  were 
mixed,  an aliquot of each unclotted mixture was tested for the presence of 
prothrombin and fibrinogen in the manner described in section 2. The data of 
this experiment are recorded in Table IV. It will be noted that the clotting 
time  of  the  mixture  of  hemophilic plasma,  streptococcal fibrinolysin,  and 
thromboplastin increased in proportion to the amount of streptococcal fibrinol- 
ysin present. In other words, the hemophilic plasma failed to clot even though 
sufficient  streptococcal fibrinolysin  was  present to result in the hydrolysis of 
some of the proteins of the plasma. 
DISCUSSION 
From the teleological point of view,  no satisfactory hypothesis has been of- 
fered to explain the presence in plasma of a potentially highly active proteolytic 
enzyme system. That proteolysis is an essential  step in the dotting of blood 
seemed an attractive hypothesis (1).  The observation that pancreatic trypsin 
dotted oxalated plasma (36) seemed to support this view.  However, none of 
the  experiments recorded in  the  literature conclusively  demonstrated  that 
proteolysis is essential  in the physiologic clotting of the blood.  The stumbling 
block to the solution of the problem has been the difficulty of preparing plasma 
proteolytic enzyme free from other clot-promoting substances.  For example, the 
proteolytic property of plasma can be activated by chloroform, and such chloro- 
form-activated preparations were observed to dot  oxalated plasma (5). How- 
ever, preparations of enzyme obtained from prothrombin-deficient plasma did 
not possess this thrombic property (section 1). Presumably, chloroform not only 
activates precursor, but converts prothrombin to thrombin. 
Others have suggested  that proteolytic enzyme activated by  streptococcal 
fibrinolysin is thromboplastic.  In Ferguson's (14) experiments, the enzyme pres- 
ent in Cohn's fraction I was activated by preparations of streptococcal fibrin- 
olysin. However, fraction I  is a  complex mixture of proteins, containing not 
only the precursor of plasma proteolytic enzyme, but also fibrinogen and anti- 
hemophilic  thromboplastin  (35). Proteolytic enzyme prepared from  plasma 
which was deficient in the known clot-promoting substances did not  possess 
thromboplastic activity (section 2). 
Finally, it has been observed that various substances which inhibited the 
activity of plasma proteolytic enzyme also inhibited blood coagulation (16-18, 
37).  The data reported do not exclude the possibility that these two effects 
were unrelated. 132  PROTEOLYTIC ENZYME  IN HUMAN  PLAS]~A. V 
In the present study, a fraction of globulin was prepared from plasma in such 
a way as to minimize  the activity of certain known substances participating in 
blood  clotting.  These  included  prothrombin,  thrombin,  fibrinogen,  plasma 
thromboplastin,  and  accelerator  globulin.  This  preparation  of globulin  con- 
tained  considerable  potential  proteolytic activity,  which  could be activated 
by streptococcal fibrinolysin.  This fraction of globulin  accelerated the clotting 
of normal platelet-deficient plasma. However, the clot-accelerating  effect of the 
globulin fraction was the same whether or not its proteolytic property had been 
activated (section  1). This suggested that the clot-accelerating  property of the 
globulin fraction was not related to its proteolytic activity. Furthermore, strep- 
tococcal fibrinolysin,  added directly to platelet-deficient plasma, activated the 
proteolytic enzyme present in the plasma without accelerating  clotting  (sec- 
tion 3). 
The nature of the clot-accelerating  property in the globulin  fraction is not 
dear. This globulin  fraction had little or no thromboplastic activity (section 
2). Perhaps the clot-accelerating factor was an artefact of preparation. Or the 
globulin  fraction  may have had  some non-specific  effect on  the  clotting  of 
plasma.  Or  perhaps  the  globulin  contained  a  relatively  heat-resistant  ac- 
celerator of clotting, not identified with plasma thromboplastin or accelerator 
globulin. Attempts at separation of the clot accelerator in the globulin from the 
precursor of plasma proteolytic enzyme have, as yet, been unsuccessful. 
Furthermore, purified  precursor (fibrinolysin)  of bovine origin,  prepared by 
Dr. E. C. Loomis,  2 accelerated the clotting of normal platelet-deficient plasma. 
The presence of this clot-accelerating factor has led to confusion  in previous 
attempts to relate proteolysis to blood clotting. 
The possibility cannot be excluded that  the precursor of plasma proteolytic 
enzyme may promote blood clotting even though it is apparently proteolytic- 
ally inactive in respect to fibrinogen,  prothrombin,  and casein.  However, the 
data presented, suggest that proteolysis by activated proteolytic enzyme is not 
an essential step in the clotting of blood. 
SUMMARY 
A fraction of globulin was prepared from human plasma which was deficient 
in prothrombin, thrombin, fibrinogen,  plasma thromboplastin, and accelerator 
globulin.  The  preparation  of globulin  contained  considerable  potential  pro- 
teolytic activity which could be activated by streptococcal fibrinolysin.  This 
fraction of globulin accelerated the clotting of normal platelet-deficient plasma. 
However, the  clot-accelerating  effect of the  globulin  fraction  was the  same 
whether or not its proteolytic property had been activated. 
The addition of streptococcal fibrinolysin  to normal platelet-deficient plasma 
2Purified bovine fibrinolysin was obtained through the courtesy of Dr. E. C. Loomis. O. D. RATNOF]~  R. C. IIART~ANN,  AND  C. L. CONLEY  133 
did not accelerate coagulation. Nor did the addition of streptococcal fibrinoly- 
sin to hemophilic platelet-deficient plasma promote its coagulation. 
The data presented suggest that proteolysis by activated plasma proteolytic 
enzyme is not an essential stage in the coagulation of the blood. 
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